TransCode Therapeutics, Inc. (RNAZ)
| Market Cap | 26.75M +160.5% |
| Revenue (ttm) | n/a |
| Net Income | -46.28M |
| EPS | -51.08 |
| Shares Out | 16.93M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,088 |
| Open | 1.600 |
| Previous Close | 1.630 |
| Day's Range | 1.600 - 1.600 |
| 52-Week Range | 1.520 - 12.600 |
| Beta | 1.26 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 14, 2026 |
About RNAZ
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company’s therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical... [Read more]
Financial Performance
Financial StatementsNews
Transcode Therapeutics begins formal strategic process to evaluate opportunities
TransCode Therapeutics (RNAZ) announced that its Board of Directors has initiated a formal strategic process to evaluate opportunities designed to maximize the value of the company and its oncology po...
TransCode Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process Intended to Maximize Value of TTX-MC138 and its Oncology Portfolio
Lead program TTX-MC138 is in Phase 2a clinical development for ctDNA-positive colorectal cancer following curative-intent treatment TransCode will evaluate strategic alternatives including licensing a...
Transcode Therapeutics presents Phase 1a clinical data for TTX-MC138 in tumors
TransCode Therapeutics (RNAZ) released its poster 1025P describing the clinical results from its Phase 1a clinical trial of TTX-MC138 at the European Society for Medical Oncology Congress 2026 in Madr...
TransCode Therapeutics Presents Phase 1a Clinical Data for TTX-MC138 at ESMO Congress 2026
Poster highlights durable disease control, acceptable tolerability and exploratory evidence of treatment-associated antitumor immune activity in patients with advanced solid tumors BOSTON, Oct. 26, 20...
TransCode Therapeutics to Present Phase 1a Clinical Trial Data for TTX-MC138 at ESMO Congress 2026
Poster presentation to highlight the Phase 1a clinical evaluation of TTX-MC138 in patients with advanced solid tumors BOSTON, Oct. 19, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ),...
Natera, Transcode to collaborate on Phase 2a trial of TTX-MC138
Natera (NTRA) and TransCode Therapeutics (RNAZ) announced a strategic collaboration in colorectal cancer, CRC. The collaboration will support enrollment for TransCode’s Phase 2a trial evaluating TTX-M...
Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
AUSTIN, Texas, & BOSTON--(BUSINESS WIRE)--Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and TransCode Therapeutics, Inc. (Nasdaq: RNAZ), a clinical stage compan...
TransCode Therapeutics Slides: Investor presentation
TransCode Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on October 2, 2026.
Transcode Therapeutics reports updated results from Phase 1a TTX-MC138 trial
TransCode Therapeutics (RNAZ) announced updated clinical data from its Phase 1a clinical trial of TTX-MC138, its novel anti-miR-10b therapeutic candidate, in patients with relapsed or refractory, unre...
TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up
Updated clinical data reinforces evidence of antitumor activity in heavily pretreated patients with advanced solid tumors In the 14 efficacy-evaluable patients: 71.4% stable disease rate 57.1% of pati...
Transcode Therapeutics announces patent advancements in Australia and Japan
TransCode Therapeutics (RNAZ) announced advancements in its global intellectual property portfolio, including the acceptance of an Australian patent application and the issuance of a Notice of Allowan...
Transcode Therapeutics announces patent advancements in Australia and Japan
TransCode Therapeutics (RNAZ) announced advancements in its global intellectual property portfolio, including the acceptance of an Australian patent application and the issuance of a Notice of Allowan...
TransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-Oncology
Allowances of Patent Applications in Australia and Japan support differentiated RNA platform for targeted cancer therapy and immune modulation BOSTON, Sept. 22, 2026 /PRNewswire/ -- TransCode Therapeu...
TransCode Therapeutics Transcript: Investor update
The update highlighted a robust oncology pipeline with TTX-MC138 as the lead asset, showing promising safety and efficacy in early trials and advancing into phase II-A for ctDNA-positive colorectal cancer. Financially, the company is well-capitalized with recent investments and no debt, and multiple clinical and regulatory milestones are expected over the next 18 months.
Transcode Therapeutics CFO Fitzgerald retiring, Tattory named interim CFO
TransCode Therapeutics (RNAZ) announced the retirement of its CFO, Tom Fitzgerald. Fitzgerald has served as CFO since July 2018. Fitzgerald will resign as CFO and as a director of the…
TransCode Therapeutics Announces Leadership Transition
Tom Fitzgerald, Chief Financial Officer, Announces his Retirement John Tattory, to become Interim Chief Financial Officer BOSTON, Sept. 10, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: R...
Transcode Therapeutics announces publication of article on TTX-MC138
TransCode Therapeutics (RNAZ) announced the publication of a peer-reviewed article in Cancers titled, “Targeting miR-10b in Breast Cancer Bone Colonization Model Using Image-Guided Nucleic Acid-Based ...
TransCode Therapeutics Announces Publication Demonstrating Survival Benefit of TTX-MC138 in Preclinical Model of Breast Cancer Bone Metastasis
Published study in Cancers highlights therapeutic potential of targeting microRNA-10b in bone metastasis with TransCode's lead therapeutic candidate BOSTON, Aug. 31, 2026 /PRNewswire/ -- TransCode The...
TransCode Therapeutics Quarterly report: Q2 2026
TransCode Therapeutics has published its Q2 2026 quarterly earnings report on August 14, 2026.
TransCode Therapeutics Transcript: AGM 2026
All proposals, including stock issuances, director elections, stock plan amendment, and auditor ratification, were approved by majority vote. No questions were raised during the Q&A session.
TransCode Therapeutics Proxy statement: Proxy filing
TransCode Therapeutics filed a proxy statement on July 17, 2026, providing details for shareholder voting and corporate governance matters.
TransCode Therapeutics Transcript: AGM 2026
The meeting was called to order, a quorum was confirmed, and the Inspector of Election was appointed. The meeting was adjourned to allow time for Nasdaq to complete its review of the company's initial listing application, with the reconvened meeting scheduled for July 20, 2026.
TransCode Therapeutics Slides: Investor presentation
TransCode Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 30, 2026.
TransCode Therapeutics Slides: Investor presentation
TransCode Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 18, 2026.
TransCode Therapeutics to Host R&D Webcast on June 18, 2026
Live Webcast to Highlight TTX-MC138 Phase 2a Trial, Three-Platform Pipeline, and Investment Thesis BOSTON, June 8, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical-stage on...